Please Wait...

ICAM 1 // Intercellular Adhesion Molecule 1

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

ICAM-1 is also known as CD54. This adhesion molecule, expressed at the surfaces of immune system and endothelial cells, is up-regulated by cytokine stimulation. ICAM-1 has 5 Ig-like domains, a transmembrane region and a small carboxyl-terminal cytoplasmic domain. ICAM1 bind two integrin: leukocyte function associated antigen (LFA1 and CD11a/CD18) and macrophage 1 antigen (Mac-1, CD11b/CD18) (Bella et al., 1998; Yang et al., 2004).

The extracellular domain of ICAM-1 can be detected in serum of healthy controls and levels are increased under disease. Serum ICAM-1 has been proposed as an indicator of inflammatory disease as soon as 1991 (Rothlein et al., 1991). The mechanism leading to the release of ICAM-1 is not fully understood and there is probably a shedding by membrane protease and an alternative RNA splicing (Witkowska and Borawska, 2004). It is possible that ADAM17 participate in the shedding of ICAM1 (in vitro studies) (Tsakadze et al., 2006).

 

SICAM-1 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum. The kit measures only the wild type allele of ICAM-1 and does not recognize ICAM-1 with the Kilifi mutation.

 

Bella, J., Kolatkar, P.R., Marlor, C.W., Greve, J.M., and Rossmann, M.G. (1998). The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 95, 4140–4145.

Rothlein, R., Mainolfi, E.A., Czajkowski, M., and Marlin, S.D. (1991). A form of circulating ICAM-1 in human serum. J. Immunol. 147, 3788–3793.

Tsakadze, N.L., Sithu, S.D., Sen, U., English, W.R., Murphy, G., and D’Souza, S.E. (2006). Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1). J. Biol. Chem. 281, 3157–3164.

Yang, Y., Jun, C.-D., Liu, J., Zhang, R., Joachimiak, A., Springer, T.A., and Wang, J. (2004). Structural Basis for Dimerization of ICAM-1 on the Cell Surface. Mol. Cell 14, 269–276.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how… https://t.co/UMYp92Puvc
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen